Mr. Slawek Smulewicz reports

MICROCOAL(TM) APPOINTS JAMES YOUNG, PHD, PAST PRESIDENT OF R&D FOR MEDIMMUNE INC., AS CHAIRMAN OF THE BOARD

Microcoal Technologies Inc. has appointed Dr. James Young as chairman of the board of directors.

Holding a PhD in microbiology and immunology from Baylor College of Medicine, Dr. Young currently serves as chairman of the board of directors of Novavax Inc. and is on the board of directors for 3-V Biosciences Inc., a private drug company. Dr. Young was with MedImmune Inc. from 1988 through 2008 following its sale to AstraZeneca PLC in 2007. During his entire tenure, Dr. Young led MedImmune's research and development organization and was directly involved in the development of approximately 20 clinical programs and commercialization of Synagis, RespiGam, CytoGam, Flumist and Ethyol. At the time of his retirement from MedImmune, Dr. Young oversaw R&D functions including approximately 1,500 people and an annual budget in excess of $700-million. Prior to MedImmune, Dr. Young was a director in the department of molecular genetics at Smith Kline and French Laboratories, now part of GlaxoSmithKline. Dr. Young has served on the boards of directors of Xencor Inc., Iomai Inc. and Arriva Pharmaceuticals Inc.

Slawek Smulewicz, chief executive officer and director of the company, reported: "We are very pleased to welcome Dr. Young to the Microcoal board.

"James's expertise as a scientist, track record of accessing government funding and building successful companies makes him exceptionally well suited to advance the company in its mission to build Microcoal as the leading clean coal company. From having been head of research and development at MedImmune Inc. since its founding in 1989 until 2008 following its sales to AstraZeneca for $15.6-billion, James has the experience and wisdom to build a world-class company.

"Lastly, I would like to take this opportunity to thank William Hudson for serving as chairman of the board for the last three years and look forward to working with him as a director as we now move forward to the next phase of Microcoal's evolution."

Upon appointment as chairman of the board of directors, Dr. Young stated: "I'm very excited by the potential for Microcoal's highly innovative microwave technology to dry coal. This approach has the potential to improve the thermal output of coal and reduce the pollution it generates and therefore be an important part of a worldwide energy solution. The recent announcement of the first commercial installation of the technology by PT Wijaya Tri Utama in Indonesia will serve to showcase the scalability of this modular microwave coal drying technology, which can be applied to coal-fired power plants worldwide. This marks the global commercial rollout for this revolutionary technology.

"Further, I am happy to be participating in the company's private placement announced yesterday and I look forward to working with management to build the finest clean coal company in the world."

William Hudson, who has served as chairman of the board for the past three years, stated: "I am pleased to have nominated Dr. Young to succeed as chairman of the board. He brings vision, vitality and expertise to the company. We all see this as a positive step advancing the success of the company and adding value for its shareholders."

We seek Safe Harbor.